The U.S. Food and Drug Administration (FDA) has approved a new drug called Zepbound for chronic weight management in adults struggling with obesity or who are overweight with at least one weight-related health issue.
What is Zepbound, and How Does It Work?
Zepbound is the brand name for the diabetes medication tirzepatide, made by the pharmaceutical company Eli Lilly. It works by mimicking hormones that help stimulate the release of insulin, increase feelings of fullness, and reduce appetite. Zepbound targets two hormone receptors: GIP and GLP-1.
Promising Weight Loss Results Seen in Trials
In clinical trials, Zepbound yielded over 20% average weight loss at higher doses over 72 weeks—stronger results than seen with other approved weight loss medications. It is recommended to be taken once a week along with a reduced-calorie diet and exercise.
Zepbound Approved for Same Uses as Competitor Wegovy
The FDA cleared Zepbound for chronic weight management in adults with obesity or who are overweight with conditions like high blood pressure or heart disease. This is the same indication as the rival drug, Wegovy. Both are taken as weekly, self-administered injections.
Potential Side Effects to Monitor
Common side effects of Zepbound include gastrointestinal issues like nausea, vomiting, constipation, and diarrhea. The label will contain warnings about risks like pancreatic inflammation, gallbladder problems, low blood sugar, kidney injury, eye damage in diabetics, and suicidal thoughts. Additionally, you can also read about- Semaglutide Cost: Is It Affordable for Weight Loss? [Detail Guide]
Monthly Costs Are Lower Than Competitor Drugs
The list price of Zepbound will be around $1,060 per month before insurance, which Eli Lilly says is 20% less than competitor semaglutide. The company aims to improve access and affordability.
Savings programs offered to patients
To further lower out-of-pocket costs, Lilly will provide a savings card for commercially insured patients to get Zepbound for $25 per 1-3 month prescription. For uninsured patients, the card allows $550 off per monthly prescription.
Zepbound is called “Revolutionary” for the weight loss market
Lilly CEO David Ricks considers Zepbound a revolutionary development for pharmaceuticals, comparing it to innovations like commercial insulin and the antidepressant Prozac. It provides a new, effective medical option for chronic weight management.
You May Find Interest: 4 Natural Appetite Suppressants that Aid in Weight Loss
